NASDAQ: CBIOCrescent Biopharma Inc Stock
$11.04+0.14 (+1.28%)
Updated Mar 23, 2026
CBIO Price
$11.04
Fair Value Price
$1.99
Market Cap
$304.23M
52 Week Low
$8.72
52 Week High
$28.77
P/E
-0.86x
P/B
1.5x
P/S
11.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.84M
Earnings
-$153.94M
Gross Margin
100%
Operating Margin
-1,381.01%
Profit Margin
-1,419.6%
Debt to Equity
0.18
Operating Cash Flow
-$72M
Beta
1.13
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CBIO Overview
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CBIO's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CBIO
Ranked#236 of 469
Ranked#236 of 469
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $33.54 | A | |
| $16.01 | A | |
| $182.32 | A |
Be the first to know about important CBIO news, forecast changes, insider trades & much more!
CBIO News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CBIO ($11.04) is overvalued by 454.77% relative to our estimate of its Fair Value price of $1.99 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CBIO ($11.04) is not significantly undervalued (454.77%) relative to our estimate of its Fair Value price of $1.99 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CBIO due diligence checks available for Premium users.
Valuation
CBIO fair value
Fair Value of CBIO stock based on Discounted Cash Flow (DCF)
Price
$11.04
Fair Value
$1.99
Overvalued by
454.77%
CBIO ($11.04) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CBIO ($11.04) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CBIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.86x
Industry
26.93x
Market
31.38x
CBIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.5x
Industry
4.63x
CBIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CBIO's financial health
Profit margin
Revenue
$10.8M
Net Income
-$92.4M
Profit Margin
-852.1%
CBIO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CBIO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$240.3M
Liabilities
$37.3M
Debt to equity
0.18
CBIO's short-term assets ($236.66M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CBIO's short-term assets ($236.66M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CBIO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$26.7M
Investing
-$72.2M
Financing
$178.9M
CBIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CBIO vs Biotech Stocks
Crescent Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.